89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafe

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , San Francisco , California , Italy , Milan , Lombardia , University Of California San Diego , Hank Mansbach , Annie Chang , Arunj Sanyal , Sheryl Seapy , Rohit Loomba , Lifesci Advisors , Division Of Gastroenterology , Nasdaq , International Liver Congress , Virginia Commonwealth University , Linkedin , Exchange Commission , Drug Administration , Week Data , Pegozafermin Trial , Metabolic Dysfunction Associated Steatohepatitis , European Association , Chief Medical Officer , California San Diego School , Molecular Pathology , Main Study , New England Journal , Breakthrough Therapy , Priority Medicines , European Medicines Agenda , Quarterly Report , Safe Harbor , Private Securities Litigation Reform Act , Sci Advisors ,